Journal of Advances in Medicine and Medical Research

Aim: To study (1) effect of pioglitazone mono-therapy on body composition in treatment naive type-2 diabetes mellitus patients and (2) relationship between changes in body composition and insulin resistance induced by pioglitazone.

Methods: Subjects: 49 newly diagnosed non-obese T2DM patients were recruited. Design: Open label observational study. Drug and Dose: pioglitazone 30 mg orally once daily for at least 6 months. Exclusion: Primary un-responsiveness at 3 months (10 subjects) and adverse effect (2 subjects). Final analysis done on 37 subjects (Mean age 47.9 years, male:female ratio 20:10) Controls: 37 healthy control subjects (Mean age 47 years M:F ratio 27:10) with normal glucose as per American Diabetes Association criteria. Study parameters were: Plasma glucose, Lipid profile, body mass index, HOMA-R, HOMA-B and body composition measured by dual-energy X-ray absorptiometry (DEXA) at start and after at least 6 months of follow up.

Results: Treatment with pioglitazone was associated with significantly decreased glycated hemoglobin (HbA1c), fasting and post-prandial plasma glucose, insulin resistance and triglycerides HDL ratio.Significant increase in total body, limb and head fat mass was observed. The trunk composition did not show significant change. The DEXA Parameters of  body composition of diabetics became comparable with controls. Significant correlation was seen between decrease in FPG, PPG, insulin resistance and increase in limb fat mass.

Conclusions: Pioglitazone alters body composition by increasing limb and head fat content, without altering trunk fat. Decrease in insulin resistance by it is related to increase in limb fat mass.